To address these knowledge gaps, this study aims to compare the clinical outcomes, hospitalization rates, and survival of children (aged 2–12 years) and adolescents (aged 13–18 years) with CF who received CFTR modulator therapies using real-world data from a large, multi-national patient cohort. The gene discussed is CFTR; the disease is cystic fibrosis.